SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Lopez Fabio (Last) (First) (Middle) EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD (Street) HAMILTON D0 HM08 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol SELLAS Life Sciences Group, Inc. [ SLS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) X Other (specify below) Former Director, 10% holder
	3. Date of Earliest Transaction (Month/Day/Year) 09/24/2018
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2018		J(1)		1,521,863	D	$0.00	0(2)	D
Common Stock	09/24/2018		J(3)		676,324	D	$0.00	0(4)	D
Common Stock	09/24/2018		J(5)		325,799	D	$0.00	0(6)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person* Lopez Fabio (Last) (First) (Middle) EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD (Street) HAMILTON D0 HM08 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director 10% Owner Officer (give title below) X Other (specify below) Former Director, 10% holder

1. Name and Address of Reporting Person* EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund (Last) (First) (Middle) C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. (Street) HAMILTON D0 HM08 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund (Last) (First) (Middle) C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. (Street) HAMILTON D0 HM08 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` (Last) (First) (Middle) C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD (Street) HAMILTON D0 HM08 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Equilibria Capital Management Ltd (Last) (First) (Middle) C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD (Street) HAMILTON D0 HM08 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Castilian Ltd. (Last) (First) (Middle) C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD (Street) HAMILTON D0 HM08 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Varibobi Financial Holdings Ltd (Last) (First) (Middle) C/O EQUILIABRIA CAPITAL MANAGEMENT LTD. O'HARA HOUSE, ONE BERMUDIANA ROAD (Street) HAMILTON D0 HM08 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Tafur Daniel (Last) (First) (Middle) C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD (Street) HAMILTON D0 HM08 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund (Last) (First) (Middle) C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD (Street) HAMILTON HM08 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund ("Sely S") distributed 1,521,863 shares to its partners on a pro rata basis, for no consideration.

2. As a partner of Sely S, Fabio Lopez, received 19,524 of the shares distributed by Sely S.

3. EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund ("Sely I") distributed 676,324 shares to its partners on a pro rata basis, for no consideration.

4. As partners of Sely I, Daniel Tafur and Equilibria Capital Management received 13,871 and 107,619, respectively, of the shares distributed by Sely I.

5. EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund ("Sely II") distributed 325,799 shares to its partners on a pro rata basis, for no consideration.

6. As partners of Sely II, Fabio Lopez and Daniel Tafur received 6,325 and 2,372, respectively, of the shares distributed by Sely II.

Remarks:

	Fabio Lopez, by /s/ Ron A. Metzger, Attorney-in-Fact	09/25/2018
	EQC Private Markets SAC Fund II Ltd EQC Biotech Sely S Fund, Daniel Tafur, Director, by /s/ Ron A. Metzger, Attorney-in-Fact	09/25/2018
	EQC Private Markets SAC Fund Ltd EQC Biotech Sely I Fund, Daniel Tafur, Director, by /s/ Ron A. Metzger, Attorney-in-Fact	09/25/2018
	EQC Private Markets SAC Fund Ltd EQC Biotech Sely II Fund, Daniel Tafur, by /s/ Ron A. Metzger, Attorney-in-Fact	09/25/2018
	EQC Private Markets II SAC Fund Ltd EQC Biotech Sely III Fund, Daniel Tafur, by /s/ Ron A. Metzger, Attorney-in-Fact	09/25/2018
	Equilibria Capital Management Limited, Daniel Tafur, by /s/ Ron A. Metzger, Attorney-in-Fact	09/25/2018
	Castilian, Ltd., Daniel Tafur, by /s/ Ron A. Metzger, Attorney-in-Fact	09/25/2018
	Varibobi Financial Holdings Ltd., Fabio Lopez, by /s/ Ron A. Metzger, Attorney-in-Fact	09/25/2018
	Daniel Tafur, by /s/ Ron A. Metzger, Attorney-in-Fact	09/25/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.